Center for Scientific Review; Notice of Closed Meetings, 77418 [05-24658]
Download as PDF
<![CDATA[
77418
Federal Register / Vol. 70, No. 250 / Friday, December 30, 2005 / Notices
Place: National Library of Medicine,
Building 38, Board Room, 2nd Floor, 8600
Rockville Pike, Bethesda, MD 20894.
Closed: February 24, 2006, 8:30 a.m. to 2
p.m.
Agenda: To review and evaluate journals
as potential titles to be indexed by the
National Library of Medicine.
Place: National Library of Medicine,
Building 38, Board Room, 2nd Floor, 8600
Rockville Pike, Bethesda, MD 20894.
Contact Person: Sheldon Kotzin, MLS,
Chief, Bibliographic Services Division,
Division of Library Operations, National
Library of Medicine, 8600 Rockville Pike,
Bldg 38A/Room 4N419, Bethesda, MD 20894,
301–496–6217,
Sheldon_Kotzin@nlm.nih.gov.
Any interested person may file written
comments with the Committee by forwarding
the statement to the Contact Person listed on
this Notice. The statement should include the
name, address, telephone number and, when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
into the building by nongovernment
employees. Persons without a government
I.D. will need to show a photo I.D. and sign
in at the security desk upon entering the
building.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: December 19, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy, NIH.
[FR Doc. 05–24649 Filed 12–29–05; 8:45 am]
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Cardiovascular Development.
Date: January 3, 2006.
Time: 2:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Larry Pinkus, PhD.,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132,
MSC 7802, Bethesda, MD 20892. (301) 435–
1214. pinkus@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; High
Performance Computing Infrastructure.
Date: January 27, 2006.
Time: 9 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Marc Rigas, PhD.,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4194,
MSC 7826, Bethesda, MD 20892. (301) 402–
1074. rigasm@csr.nih.gov.
(Catalogue of Federal Domestic
Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical
Research, 93.306, 93.333, 93.337,
93.393–93.396, 93.837–93.844, 93.846–
93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 22, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–24658 Filed 12–29–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–M
National Institutes of Health
wwhite on PROD1PC61 with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
VerDate Aug<31>2005
18:16 Dec 29, 2005
Jkt 208001
Prospective Grant of Exclusive
License: Treatment of Cardiovascular
Conditions With Nitrite Therapy
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of an exclusive
license to practice the invention
embodied in PCT patent applications
PCT/US2004/21985 and PCT/US2004/
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
22232, filed July 9, 2004, both entitled
‘‘Use of Nitrite Salts for the Treatment
of Cardiovascular Conditions’’ [HHS
Reference Number: E–254–2003/2–3–
PCT–01], to Hope Medical Enterprises,
Inc., dba Hope PharmaceuticalsTM, an
Arizona S-Corporation having a
principle place of business in
Scottsdale, Arizona. The field of use
may be limited to the use of nitrite salts
for the treatment of cerebral vasospasm
following subarachnoid hemorrhage
and/or cardiovascular conditions. The
United States of America is an assignee
of the patent rights in these inventions.
DATES: Only written comments and/or
application for a license, which are
received by the NIH Office of
Technology Transfer on or before
February 28, 2006 will be considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Susan Carson, D.Phil., Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
E-mail: carsonsu@od.nih.gov;
Telephone: (301) 435–5020; Facsimile:
(301) 402–0220.
SUPPLEMENTARY INFORMATION: A wide
variety of disease indications, including
cardiovascular and respiratory diseases,
have been treated by different
therapeutic classes of compounds that
are able to increase blood flow and act
as vasodilators. The core invention is
the unexpected finding that low,
physiological and non-toxic
concentrations of sodium nitrite are able
to increase blood flow and produce
vasodilation by infused and nebulized
routes of administration. Proof of
concept data has been obtained in
animal models for (1) myocardial and
hepatic ischemia and reperfusion injury
[J. Clin. Invest. (2005) 115, 1232–1240],
(2) neonatal pulmonary hypertension in
a neonate lamb model [Nature Medicine
(2004) 10, 1122–1127] and (3) control of
delayed cerebral vasospasm following
subarachnoid hemorrhage in a primate
model [JAMA (2005) 293, 1477–1484].
The implications of these results point
to the use of nitrite as a potential costeffective platform therapy for a wide
variety of disease indications
characterized broadly by constricted
blood flow or hypoxia. Method of use
claims for nitrite salt formulations are
directed to conditions associated with
high blood pressure, decreased blood
flow or hemolytic disease and for the
treatment of specific conditions such as
pulmonary hypertension, cerebral artery
vasospasm and hepatic, cardiac or brain
ischemia-reperfusion injury.
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 70, Number 250 (Friday, December 30, 2005)]
[Notices]
[Page 77418]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-24658]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Cardiovascular Development.
Date: January 3, 2006.
Time: 2:30 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone Conference Call).
Contact Person: Larry Pinkus, PhD., Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD
20892. (301) 435-1214. pinkus@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; High Performance Computing Infrastructure.
Date: January 27, 2006.
Time: 9 a.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda,
MD 20814.
Contact Person: Marc Rigas, PhD., Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4194, MSC 7826, Bethesda, MD
20892. (301) 402-1074. rigasm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: December 22, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-24658 Filed 12-29-05; 8:45 am]
BILLING CODE 4140-01-M
